7.89
7.89 (0%)
As of Apr 17, 2025
Cullinan Oncology, Inc [CGEM]
Source:
Company Overview
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to creating new standards of care for patients. Our strategy is to identify high-impact targets, which we define as those that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer, and then select what we believe is the optimal therapeutic modality for those targets.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | ( 617 ) 410-4650 |
| Industry | manufacturing |
| CEO | Nadim Ahmed |
| Website | www.cullinantx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-196.9 |
| Net Income | $-167.6 |
| Net Cash | $-15.4 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -30.3% |
| Profit as % of Stockholder Equity | -28.4% |
Management Effectiveness
| Return on Equity | -28.4% |
| Return on Assets | -27% |
| Turnover Ratio | |
| EBITA | $-196.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $621.8 |
| Total Liabilities | $31.5 |
| Operating Cash Flow | $-145.3 |
| Investing Cash Flow | $-136.3 |
| Financing Cash Flow | $266.2 |
